Cancer Treatment News and Research

RSS

Long-term monitoring and education needed to protect lungs of young patients

St. Jude Children's Research Hospital investigators have identified childhood cancer survivors who are at increased risk for deteriorating lung health, in part due to the lifesaving bone marrow transplants they underwent years earlier.

16 Apr 2010

IBA's PBS system for Proton Therapy granted CE Mark

IBA's second generation Pencil Beam Scanning system for Proton Therapy, which further enhances the performance of anti-cancer proton treatments, has been granted the CE Mark, certifying that the product has met European Union medical device regulations.

16 Apr 2010

Early, accurate detection of superficial bladder cancer with Olympus PDD

With Olympus photodynamic diagnosis (PDD), superficial bladder cancer can be detected earlier, easier and more accurately. Bladder cancer is diagnosed by cystoscopy, the endoscopic introduction of a light source through the urethra (transurethral) into the bladder. The imaging technology PDD uses blue light to increase the contrast between tumour tissue (red) and healthy tissue (blue).

From Evident Corporation - Life Sciences 15 Apr 2010

Foundation Medicine completes $25M Series A financing led by Third Rock Ventures

Foundation Medicine, a personalized cancer medicine company that aims to bring comprehensive cancer genome analysis into routine clinical care, today announced it has completed a $25 million Series A financing led by Third Rock Ventures.

15 Apr 2010

Decoding genomes from 25,000 cancer samples

The International Cancer Genome Consortium (ICGC) today set out its bold plan to decode the genomes from 25,000 cancer samples and create a resource of freely available data that will help cancer researchers around the world. The publication outlines research design and projects as well as the important ethical framework for this science.

15 Apr 2010

Cancer patients continue to be affected by FN as a result of chemotherapy: Survey

Thirty percent of patients surveyed experienced an infection as a result of chemotherapy, 45 percent of which were associated with neutropenia or febrile neutropenia according to findings from a pan-European patient and nurse survey presented today at the 7th Annual European Oncology Nursing Society Spring Convention.

15 Apr 2010

Drug boosting production of immune system protein worsens TB

An experimental drug that boosts production of the immune system protein interferon worsens tuberculosis (TB) in mice, according to scientists from the National Institutes of Health. The drug acts indirectly by drawing certain immune cells, in which Mycobacterium tuberculosis (M.tb) bacteria thrive, to the lungs. The findings may have potential implications for the care of people infected with TB, the authors note. The research is reported in the May 3 issue of Journal of Clinical Investigation, now available online.

13 Apr 2010

Research on efficacy of yoga in breast cancer treatment attracts award of over $4.5M

In an ongoing effort to scientifically validate the age-old belief that mind-body interventions have a beneficial impact on the health of patients, The University of Texas M. D. Anderson Cancer Center has been awarded more than $4.5 million to study the efficacy of incorporating yoga into the treatment program of women with breast cancer.

13 Apr 2010

Despite international guidelines, wide variations exist in breast cancer care

A global study of nearly 10,000 women with early breast cancer has found wide variations in how they were treated, despite international consensus on best practice, according to the May issue of the British Journal of Surgery.

13 Apr 2010

Global study shows wide variations in treatment of women with early breast cancer

12 Apr 2010

U-M Medical School researchers earn $366M in NIH research funding in fiscal year 2009

University of Michigan Medical School physicians and scientists earned more than $366 million in National Institutes of Health research funding in federal fiscal year 2009, according to NIH data. In all, the School's faculty brought in more than $435 million in research funding from all sources in U-M fiscal year 2009.

12 Apr 2010

Æterna Zentaris commences perifosine Phase 3 registration trial

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced the initiation of a Phase 3 registration clinical trial with perifosine (KRX-0401) ), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer.

9 Apr 2010

Bayard Advertising Agency selected as Recruitment Advertising Agency of Record by CTCA

Bayard Advertising Agency, Inc., an integrated branding and communications agency serving B2B and B2C clients in a broad array of industries, announces its selection as Recruitment Advertising Agency of Record by Cancer Treatment Centers of America.

8 Apr 2010

The $560 million for cancer centers not enough says Cancer Council

The Federal Government has announced a $560 million for new or upgraded cancer centres across Australia this week. The Cancer Council of Australia while welcoming this gesture has said that this is not the complete solution when it comes to helping regional and rural patients of Australia. This statement was made by the CEO Ian Olver who said that this “unprecedented” amount of money can go a long way to help but more support is needed. One of the regional cancer support networks has gone further to criticize the fact that so much is doled out in patient accommodation instead of advanced cancer treatment and care services.

8 Apr 2010

Cytrx to commence Phase 2 trial of bafetinib for advanced prostate cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced plans to initiate a Phase 2 proof-of-concept clinical trial in the second half of 2010 to evaluate the effectiveness and safety of its oncology drug candidate bafetinib (formerly known as INNO-406) in patients with an advanced form of prostate cancer known as metastatic hormone-refractory prostate cancer.

7 Apr 2010

Avastin approval to drive ovarian cancer drug market to $1.5 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the ovarian cancer drug market -- driven by the approval and rapid uptake of Roche/Genentech/Chugai's Avastin -- will more than triple from $449 million in 2008 to just under $1.5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

7 Apr 2010

CancerGuide Diagnostics, Duke University form cancer research collaboration and licensing agreement

CancerGuide Diagnostics™, Inc. today announced that it has entered into a research collaboration and licensing agreement with Duke University to discover and develop tests to support individualized cancer treatment decisions.

7 Apr 2010

Newer treatments, closer monitoring of childhood cancer may improve longevity

Although more children today are surviving cancer than ever before, young patients successfully treated in the 1970s and 80s may live a decade less, on average, than the general population, according to a study from Dana-Farber Cancer Institute and the Harvard School of Public Health.

7 Apr 2010

Identification and elimination of cancer stem cells

A new field of cancer research could explain why some cancers that appear to have been cured can rear their ugly head or spread to other organs.

3 Apr 2010

Cancer research at Georgia Tech: Report

Cancer treatment typically involves surgery, radiation therapy, chemotherapy, hormone therapy or biological therapy. An oncologist may use one therapy or a combination of methods, depending on the type and location of the cancer, whether the disease has spread, the patient's age and general health, and other factors.

3 Apr 2010